Transcatheter Tricuspid Valve-in-Valve and Valve-in-Ring Implantation: the TRIVIR registry
JACC: Cardiovascular Interventions · 2026-10
DOI: 10.1016/j.jcin.2026.10.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2026-10. Verfasst von Razvan Berghi und 33 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Transcatheter tricuspid valve-in-valve (TViV) and valve-in-ring (TViR) procedures are increasingly used; however, data on clinical outcomes, valve performance, and symptomatic improvement remain limited.
Objectives
To evaluate a real-world multicenter cohort undergoing transcatheter TViV and TViR procedures.
Methods
We conducted an international multicenter registry including patients undergoing TViV/TViR procedures. The TRIVIR Registry evaluated all-cause mortality and a composite endpoint (CE), defined as all-cause mortality, heart failure (HF) hospitalization, and tricuspid bioprosthesis degeneration during follow-up.
Results
Between 2012 and 2025, 75 patients underwent TViV (n=62) or TViR (n=13) across 16 centers using Sapien (88%) or Myval (12%) valves. Median follow up was 1.86 years (IQR 0.10-2.59). Mean age was 62±13 years, and 69% were women. NYHA class III–IV decreased from 72% at baseline to 13% at 1-3 months and remained low during follow-up. No 30-day deaths occurred, while periprocedural complications occurred in 24% of procedures, mostly minor (17.3%). At 3 years, the Kaplan–Meier estimates of all-cause mortality and CE were 35.6% and 42.9%, and the cumulative incidences of HF hospitalization and tricuspid bioprosthesis degeneration were 16.6% and 11.4%, respectively. Patients who died had markers of advanced disease, including higher NT-proBNP levels, greater diuretic requirements, more frequent pacing/CRT implantation, and higher procedural complication rates.
Conclusions
TViV/TViR represents a viable treatment strategy and provided sustained symptomatic improvement in high-risk patients. Patients who died exhibited a more advanced clinical profile, highlighting the importance of appropriate patient selection, early referral, and treatment in experienced centers.
Zitieren
APA
Berghi, R., George, I., Ancona, M. B. M., Amat-Santos, I. J., Brambilla, N., Delewi, R., Berman, E., Andreka, J., Chen, S., Vella, C., García-Gómez, M., Perkan, A., Vitrella, G., Barbati, G., Lesizza, P., Costa, G., Barthelemy, O., Lebreton, G., Pancaldi, E., …, & Fabris, E. (2026). Transcatheter Tricuspid Valve-in-Valve and Valve-in-Ring Implantation: the TRIVIR registry. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2026.10.025
Vancouver
Berghi R, George I, Ancona MBM, Amat-Santos IJ, Brambilla N, Delewi R, et al. Transcatheter Tricuspid Valve-in-Valve and Valve-in-Ring Implantation: the TRIVIR registry. JACC: Cardiovascular Interventions. 2026. doi:10.1016/j.jcin.2026.10.025
BibTeX
@article{Berghi2026,
author = {Berghi, Razvan and George, Isaac and Ancona, Marco Bruno Maria and Amat-Santos, Ignacio J. and Brambilla, Nedy and Delewi, Ronak and Berman, Eliza and Andreka, Judit and Chen, Shmuel and Vella, Ciro and García-Gómez, Mario and Perkan, Andrea and Vitrella, Giancarlo and Barbati, Giulia and Lesizza, Pierluigi and Costa, Giuliano and Barthelemy, Olivier and Lebreton, Guillaume and Pancaldi, Edoardo and Beijk, Marcel A.M. and Crociani, Maria Federica and Dubois, Christophe and Mangieri, Antonio and Porto, Italo and Adamo, Marianna and Trani, Carlo and Marco, Federico De and Toth, Gábor and Bedogni, Francesco and Burzotta, Francesco and Mario, Carlo di and Sinagra, Gianfranco and Capodanno, Davide and Fabris, Enrico},
title = {Transcatheter Tricuspid Valve-in-Valve and Valve-in-Ring Implantation: the TRIVIR registry},
journal = {JACC: Cardiovascular Interventions},
year = {2026},
doi = {10.1016/j.jcin.2026.10.025}
}
EUVIMED